

FIRST LIGHT 23 October 2025

### RESEARCH

IDFC FIRST BANK | TARGET: Rs 89 | +16% | BUY

Asset quality improving with receding MFI pain

AU SMALL FINANCE BANK | TARGET: Rs 829 | -4% | HOLD

Business momentum stays strong, asset quality improving

FEDERAL BANK | TARGET: Rs 263 | +16% | BUY

Asset quality improved; business momentum moderates

RBL BANK | TARGET: Rs 292 | -3% | HOLD

Return metrics remain moderate

## **SUMMARY**

## **IDFC FIRST BANK**

- PAT missed estimates mainly due to higher opex; return ratio likely to improve on operating leverage and asset quality improvement
- Credit growth remains robust with a leading CASA ratio; asset quality improved with the MFI pain receding
- Maintain BUY with revised TP of Rs 89 (Rs 83 earlier), set at 1.4x Sep'27E ABV

Click here for the full report.

# **AU SMALL FINANCE BANK**

- PPoP largely in line with estimates; lower provisions resulted in higher PAT; business momentum stays strong
- Asset quality improved marginally, driven by lower slippages
- Maintain HOLD with revised TP of Rs 829 (from Rs 741) and roll over the valuation to 2.5x Sep'27E ABV

Click here for the full report.

BOBCAPS Research research@bobcaps.in





## **FEDERAL BANK**

- PAT beat estimates, largely driven by NIMs surprise; asset quality improved
- Focus on medium-yielding segments and proposal for fund raising
- Maintain BUY with revised TP of Rs 263 (Rs 242 earlier), valuing the stock at 1.4x Sep'27E ABV

Click here for the full report.

## **RBL BANK**

- ENBD to acquire upto 60% stake in RBK through preferential issue of ~USD
   3bn, subject to shareholder and regulatory approvals
- Return ratios remain moderate; asset quality showing signs of improvement
- Maintain HOLD with TP of Rs 292 (from Rs 253), valuation of 0.9x Sep'27E ABV (0.8x earlier)

Click here for the full report.

EQUITY RESEARCH 23 October 2025



BUY
TP: Rs 89 | A 16%

**IDFC FIRST BANK** 

Banking

23 October 2025

## Asset quality improving with receding MFI pain

- PAT missed estimates mainly due to higher opex; return ratio likely to improve on operating leverage and asset quality improvement
- Credit growth remains robust with a leading CASA ratio; asset quality improved with the MFI pain receding
- Maintain BUY with revised TP of Rs 89 (Rs 83 earlier), set at 1.4x
   Sep'27E ABV

Niraj Jalan Research Analyst Vijiya Rao Research Analyst research@bobcaps.in

PAT missed estimates; return ratio likely to improve: IDFCFB missed our PAT estimates by 10% to Rs 3.5bn in Q2FY26, mainly due to higher opex and lower non-interest income. With lower trading gain of Rs 560mn (Q2FY26) vs Rs 4,950mn (Q1FY26), given the rise in yields, non-interest income fell by 15.1% QoQ. C/I ratio remains elevated to 73.2% (+3.3% YoY; +4.4% QoQ). This was mainly due to decline in the share of high-yielding MFI to 2.7% of AUM vs. 3.3% in Q1FY26. This also impacted NIMs, which declined to 5.6% (-10bps QoQ), along with pass through of repo rate cuts and higher SA interest rates. Management stated that they are unlikely to reduce SA rates in the near term, as it prefers to reduce LDR ratio to mid-80s vs 92.9% (Q2FY26). Management expects NIMs to have largely bottomed out in Q2FY26 and likely improve to 5.8% in Q4FY26, factoring in one more rate cut. Also, the bank expects credit costs to be ~2.0–2.05% of loans in FY26 (2.6% in FY25). With portfolio growth expected at a healthy CAGR of ~19% in FY25-28E, cost efficiency likely to kick in and credit cost to decline, return ratio will improve.

Credit growth remains robust with leading CASA ratio: Bank reported robust loan growth with net advances up by 19.5% YoY. This was supported by strong deposit growth of 23.8% YoY, largely led by rise in CASA deposits (+26.8% YoY). As a result, bank reported industry leading CASA ratio of 50.1% (Q2FY26).

Asset quality improved with MFI pain receding: AQ improved with GNPA ratio falling to 1.86% (-11bps QoQ) in Q2FY26. This improvement was led by a decline in slippages to 3.71% (-56bps QoQ), coupled with a rise in w/offs to Rs 17.7bn (+12.8% QoQ). We note that slippage in MFI book fell sharply to Rs 2.5bn vs. Rs 5.1bn (Q1FY26). Also, the SMA 1+2 pool reduced significantly by 88 bps to 1.76%, indicating receding stress in MFI book. Further, the bank utilised Rs 0.75bn of contingency provision buffer, while still maintains Rs 2.4bn as contingency on MFI.

**Maintain BUY:** We expect credit growth at ~19% CAGR in FY25-FY28E. Early signs of AQ improvement would be the key to improving RoA to 0.6-1.1% in FY26-FY28E. We maintain BUY and roll over valuation to 1.4x Sep'27E ABV with revised TP of Rs 89 (Rs 83 earlier).

### Key changes

Target	Rating	
<b>A</b>	<b>∢</b> ▶	

Ticker/Price	IDFCBK IN/Rs 77
Market cap	US\$ 7.5bn
Free float	100%
3M ADV	US\$ 15.5mn
52wk high/low	Rs 78/Rs 52
Promoter/FPI/DII	0%/32%/22%

Source: NSE | Price as of 21 Oct 2025

## **Key financials**

Y/E 31 Mar	FY25A	FY26E	FY27E
NII (Rs mn)	1,92,920	2,11,044	2,64,951
NII growth (%)	17.3	9.4	25.5
Adj. net profit (Rs mn)	15,248	23,746	43,958
EPS (Rs)	2.1	3.0	5.1
Consensus EPS (Rs)	2.1	3.2	5.5
P/E (x)	36.2	25.7	15.0
P/BV (x)	1.5	1.4	1.3
ROA (%)	0.5	0.6	1.0
ROE (%)	4.3	5.5	8.9

Source: Company, Bloomberg, BOBCAPS Research

## Stock performance







HOLD TP: Rs 829 | ¥ 4%

## AU SMALL FINANCE BANK

Banking

22 October 2025

## Business momentum stays strong, asset quality improving

- PPoP largely in line with estimates; lower provisions resulted in higher PAT; business momentum stays strong
- Asset quality improved marginally, driven by lower slippages
- Maintain HOLD with revised TP of Rs 829 (from Rs 741) and roll over the valuation to 2.5x Sep'27E ABV

Niraj Jalan Research Analyst Vijiya Rao Research Analyst research@bobcaps.in

## PPoP largely in line with estimates; lower provisions resulted in higher PAT:

PPoP was largely in line with estimates (-1%) at Rs 12.1bn (+6.9% YoY). This was supported by healthy loan growth (+22% YoY) and a sequential rise in NIMs to 5.5% (+10bps QoQ). Management expects NIMs to expand in the next couple of quarters as deposit reprices. However, PAT was 6% higher than our estimates at Rs 5.6bn (-1.8% YoY), mainly due to lower credit cost vs our estimates by 7%. However, provisions remain elevated at Rs 4.8bn (+28.9% YoY; -9.8% QoQ) or credit cost of 1.3% of ATA. Around 50% of CC was from credit card and MFI segments. With stress easing in MFI, management guided credit costs to be <1% of ATA for FY26.

Business momentum stays strong: AUBANK witnessed net advance growth of 22% YoY, which was twice the system growth. Secured retail assets (wheels, MBL, HL and GL) accounted for 67.3% of total loans, followed by Commercial Banking (CB) (20.7%) and unsecured (7.6%) and others (4.3%). Management stated that secured retail assets will continue to grow at a high pace, given rise in distribution expansion in the states of AP, Karnataka, TN, Telangana, UP and West Bengal. Deposit growth stays strong at 20.8% YoY (Sep'25) and was ~2x the system growth.

Asset quality improved marginally, driven by lower slippages: GNPA ratio improved marginally to 2.41% (-6bps QoQ), largely driven by lower slippages of Rs 9.1bn (-11.6% QoQ) or slippage ratio of 3.7% (-72 bps QoQ). The reduction in slippages was due to lower slippages in cards, mortgages and CB. Further, CE in non-overdue MFI loans improved to 98.9% in Q2FY26 vs 98.3% in Q1FY26. Also, the SMA book improved to 2.9% (Sep'25) vs 4.3% (Jun'25), indicating improving early bucket delinquency. Management expects high recovery in the Wheels segment in H2FY26 and expects credit card to normalise by the end of FY26.

**Maintain HOLD:** AUBANK received in-principle approval from RBI for conversion into a universal bank in Aug'25. We believe the bank's current valuations appear stretched relative to underlying fundamentals. We expect the bank to deliver RoA of 1.8% by FY28E. We maintain HOLD with revised TP of Rs 829 (from Rs 741) and roll over the valuation to 2.5x Sep'27E ABV.

## Key changes

Target	Rating	
<b>A</b>	<b>∢</b> ▶	

Ticker/Price	AUBANK IN/Rs 861
Market cap	US\$ 7.3bn
Free float	77%
3M ADV	US\$ 24.5mn
52wk high/low	Rs 872/Rs 478
Promoter/FPI/DII	23%/35%/32%

Source: NSE | Price as of 21 Oct 2025

## **Key financials**

Y/E 31 Mar	FY25A	FY26E	FY27E
NII (Rs mn)	80,116	93,729	1,16,336
NII growth (%)	55.4	17.0	24.1
Adj. net profit (Rs mn)	21,059	25,587	35,401
EPS (Rs)	29.8	34.4	47.5
Consensus EPS (Rs)	28.2	34.4	46.6
P/E (x)	28.9	25.1	18.1
P/BV (x)	3.7	3.3	2.8
ROA (%)	1.6	1.5	1.7
ROE (%)	14.2	13.9	16.6

Source: Company, Bloomberg, BOBCAPS Research

## Stock performance







BUY TP: Rs 263 | ▲ 16%

**FEDERAL BANK** 

Banking

21 October 2025

## Asset quality improved; business momentum moderates

- PAT beat estimates, largely driven by NIMs surprise; asset quality improved
- Focus on medium-yielding segments and proposal for fund raising
- Maintain BUY with revised TP of Rs 263 (Rs 242 earlier), valuing the stock at 1.4x Sep'27E ABV

Niraj Jalan Research Analyst Vijiya Rao Research Analyst research@bobcaps.in

PAT beat estimates, largely driven by NIMs surprise: PAT at Rs 9.6bn (+11% QoQ) was 9% above our estimates, mainly due to surprise improvement in NIMs to 3.06% (+12bps QoQ). Despite a decline in yield on advances (-18bps), NIMs improved due to higher decline in CoD (-21bps QoQ) to 5.6%. Increase in CASA ratio to 31% (+66bps QoQ) also resulted in CoD improvement. Further, earnings were supported by lower CC of 50bps vs 65bps (Q1FY26) amid the easing MFI stress. Management guided for CC of ~55bps in FY26. RoA will likely improve to 1.1-1.3% in FY26-28E, driven by its focus on fee income growth, CASA and change in loan mix (medium-yielding).

**Asset quality improved:** AQ improved with GNPA ratio declining to 1.83% (-8bps QoQ), mainly driven by lower slippages, which stood at Rs 5.8bn (-12% QoQ). Slippage came largely from MFI segment (1.6% of gross loans), which accounted for 34% of the total slippage in Q2FY26. Management stated that the MFI stress peaked last quarter and is moderating every month, yet to be fully normalised.

Focus on medium-yielding segments and proposal for fund raising: FB witnessed moderate loan growth (+6.2% YoY) as of Sep'25 and was below the system loan growth. We note that FB is recalibrating loan mix and focuses on medium-yielding segments (CV/CE, LAP, Auto, Gold) that saw a rise in its gross advances share to 43.8% (42.5% in Q2FY25). Management's strategy for loan mix and growth is to a) scale up the high-yielding MFI (-2% YoY) and personal loan (-7% YoY) segments once the external environment stabilises b) expect to grow at a high pace in LAP and BuB segments over the next few quarters. We note that the bank has scheduled a board meeting on Oct 24, 2025 to approve the proposal to raise funds subject to regulatory / statutory approvals. We await further clarity on the purpose and details of fund raise.

**Maintain BUY:** We expect the fruition of FB's strategic initiatives to take time and would be watchful. We model advances growth of 15% CAGR over FY25-28E with RoA/RoE of 1.3%/13.9% in FY28E. We maintain BUY and roll over valuation to 1.4x Sep'27E ABV with TP of Rs 263 (Rs 242 earlier).

## **Key changes**

Target	Rating	
<b>A</b>	<b>∢</b> ▶	

Ticker/Price	FB IN/Rs 227
Market cap	US\$ 6.3bn
Free float	100%
3M ADV	US\$ 18.0mn
52wk high/low	Rs 230/Rs 173
Promoter/FPI/DII	0%/26%/50%

Source: NSE | Price as of 20 Oct 2025

# **Key financials**

Y/E 31 Mar	FY25A	FY26E	FY27E
NII (Rs mn)	94,680	1,04,118	1,23,702
NII growth (%)	14.2	10.0	18.8
Adj. net profit (Rs mn)	40,519	39,705	50,973
EPS (Rs)	16.6	16.2	20.8
Consensus EPS (Rs)	16.6	16.0	20.2
P/E (x)	13.7	14.0	10.9
P/BV (x)	1.7	1.5	1.3
ROA (%)	1.2	1.1	1.2
ROE (%)	13.0	11.3	12.9

Source: Company, Bloomberg, BOBCAPS Research

# Stock performance







HOLD TP: Rs 292 | ¥ 3%

**RBL BANK** 

Banking

20 October 2025

### Return metrics remain moderate

- ENBD to acquire upto 60% stake in RBK through preferential issue of ~USD 3bn, subject to shareholder and regulatory approvals
- Return ratios remain moderate; asset quality showing signs of improvement
- Maintain HOLD with TP of Rs 292 (from Rs 253), valuation of 0.9x
   Sep'27E ABV (0.8x earlier)

Niraj Jalan Research Analyst Vijiya Rao Research Analyst research@bobcaps.in

**ENBD to acquire up to 60% stake in RBK**: Emirates NBD PJSC (ENBD) plans to acquire up to 60% stake in RBK by infusing ~USD 3bn through preferential issue. The deal is subject to shareholders and various regulatory approvals. This will also involve amalgamation of ENBD's India branches with RBK. It will augment RBK's capital position with net worth rising by 3x to Rs 420bn+. The bank's credit rating (CARE AA-(Stable)) might improve, which would lead to lower CoF and would influence its risk-reward choices. Also, this will enable the bank to scale up through branch expansion and improve digital capabilities.

Earnings impacted by high C/I ratio; secured retail products turned profitable while NIMs likely to improve: PPoP declined 20% YoY, due to high C/I ratio at 70.7% (64.2% in Q2FY25). NII was down 4% YoY to Rs 15.5bn in Q2FY26, mainly due to falling share of unsecured book (high-yield), coupled with a decline in yield on loans by 20bps QoQ to 12.3%, due to repo rate cuts. NIMs were stable on QoQ basis at 4.5% with the management expecting margins to improve by 10-15bps QoQ from Q3FY26 and exit NIMs would be ~4.75-4.8% by Q4FY26. Further, PAT was down 11% QoQ to Rs 1.8bn, given the rise in provisions to Rs 5bn (+13% QoQ). Return profile remains moderate with RoA/ RoE of 0.5%/ 4.4% in Q2FY26. Management stated that secured retail products, except for prime housing that was in the investment phase in the last 2 years, have turned PBT positive.

Asset quality showing signs of improvement: GNPA declined to 2.32% (-45bps QoQ), largely driven by a) improvement in the slippage ratio to 3.9% (Q2FY26) vs. 4.6% (Q1FY26) b) high w/offs of Rs 10.4bn (+48% QoQ). Unsecured retail accounted for 85% of total slippage in Q2FY26. Also, total SMA book in JLG improved to 3.5% (Sep'25) vs 5.4% (Jun'25). Management expects slippage in CC and PL to normalise in the next couple of quarters.

**Maintain HOLD:** We believe lower growth in unsecured retail (high RoA) and high C/I will likely result in moderate return ratios. We maintain HOLD and roll over valuation at 0.9x Sep'27E ABV (0.8x earlier) vs 3Y average P/ABV of 0.8x with revised TP of Rs 292 (from Rs 253).

## **Key changes**

Target	Rating	
<b>A</b>	<b>∢</b> ▶	

Ticker/Price	RBK IN/Rs 300
Market cap	US\$ 2.1bn
Free float	100%
3M ADV	US\$ 42.1mn
52wk high/low	Rs 308/Rs 146
Promoter/FPI/DII	0%/15%/35%

Source: NSE | Price as of 17 Oct 2025

# **Key financials**

Y/E 31 Mar	FY25A	FY26E	FY27E
NII (Rs mn)	64,630	69,677	83,220
NII growth (%)	7.0	7.8	19.4
Adj. net profit (Rs mn)	6,954	11,736	17,615
EPS (Rs)	11.5	19.3	29.0
Consensus EPS (Rs)	11.5	18.2	27.9
P/E (x)	26.1	15.5	10.3
P/BV (x)	1.2	1.1	1.0
ROA (%)	0.5	0.8	1.0
ROE (%)	4.6	7.3	10.1

Source: Company, Bloomberg, BOBCAPS Research

## Stock performance







NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## **Disclaimer**

Name of the Research Entity: BOB Capital Markets Limited

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025

Brand Name: BOBCAPS

Trade Name: www.barodaetrade.com CIN: U65999MH1996GOI098009

Logo:



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

#### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

#### **Analyst certification**

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

EQUITY RESEARCH 23 October 2025



BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

## No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations

EQUITY RESEARCH 23 October 2025